Adult Dosing
Severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support
- Pre-myelotoxic therapy
- 60 mcg/kg/day IV bolus for 3 consecutive days before myelotoxic therapy, with third dose 24-48 hrs before myelotoxic therapy
- Post-myelotoxic therapy
- 60 mcg/kg/day IV bolus for 3 consecutive days post-myelotoxic therapy
- Note: Administer the first of these doses after, but on the same day of hematopoietic stem cell infusion and at least 4 days after the most recent administration of palifermin
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
- The effects of the drug on stimulation of KGF receptor-expressing, non-hematopoietic tumors in patients are not known; safety and efficacy in patients with non-hematologic malignancies have not been established
- It enhances the growth of human epithelial tumor cell lines in vitro and increases the rate of tumor cell line growth in a human carcinoma xenograft model
Caution: Use cautiously in
- Non-hematologic malignancy
Pregnancy Category:C
Breastfeeding: It is unknown whether the drug is excreted in human milk; manufacturer advises caution when administered to a nursing woman.
